NICE draft guidance recommends against Biogen's Spinraza for SMA
U.K.’s NICE published draft guidance recommending against the use of Spinraza nusinersen from Biogen Inc. (NASDAQ:BIIB) to treat spinal muscular atrophy. The committee cited significant uncertainties around Spinraza's long-term benefits, as well as the drug's “extremely high” cost.
Based on Spinraza's list price, NICE concluded that the drug's incremental cost-effectiveness ratio (ICER) is likely in the range of £400,000 ($509,558) to £600,000 ($764,337) per quality-adjusted life year (QALY) gained compared with standard of care. The committee said that even with Biogen's proposed undisclosed discount, the therapy’s cost is too high to be considered cost effective by the NHS...
BCIQ Company Profiles
BCIQ Target Profiles